Herantis Pharma hires Spark Therapeutics' Juha Savola as CMO ahead of pivotal Parkinson's trial

What Herantis is trying to accomplish

Savola arrives as Herantis moves from early clinical validation to preparing one of the company's most important value-creation milestones. 

Following positive FDA feedback in June, the company is finalizing a Phase 2a proof-of-concept study designed to enroll around 100 newly diagnosed Parkinson's disease patients across Europe, while preserving the option to activate US sites should it submit an Investigational New Drug application. The study is expected to begin in 2027 and will evaluate twice-weekly subcutaneous dosing of HER-096 over six months, followed by a six-month open-label extension.

Financing remains equally important. As a pre-revenue biotechnology company, Herantis is working to complete funding for the Phase 2 program through a combination of strategic partnerships, equity financing, and non-dilutive funding. Management has said more than half of the required funding has already been secured or identified, supported by an expected EUR 8 million Horizon Europe grant awarded to a consortium led by Herantis.

The company is also trying to improve the quality and efficiency of the trial itself. In May, Herantis partnered with Basel-based TechBio company Indivi to integrate smartphone-based digital biomarkers capable of measuring motor and cognitive function, aiming to detect treatment effects more sensitively than conventional clinical assessments. 

Bringing Savola into the executive team adds experience that aligns closely with those objectives. His background leading global clinical programs and working with both the FDA and the European Medicines Agency is expected to support regulatory execution, clinical operations, and discussions with potential development partners as HER-096 advances.

Investor watchpoints

The biggest question for investors is whether Herantis can convert recent momentum into clinical progress. Positive FDA feedback, non-dilutive funding, and a strengthened leadership team have improved the company's position as it prepares for the Phase 2 program. With negative equity reported at the end of 2025, financing developments are likely to remain as important as scientific milestones.

The next catalyst will be the transition from preparation to patient enrollment. Investors will be watching for confirmation that the Phase 2a study begins on schedule in 2027, along with updates on recruitment, regulatory interactions and any decision to file an IND that would allow US clinical sites to participate. Each milestone would further validate the company's development strategy.

Strategic partnerships could become another inflection point. Management continues to evaluate potential partners alongside financing alternatives, and any collaboration with a larger pharmaceutical company would provide both additional resources and external validation for HER-096 as Herantis seeks to position the therapy as a disease-modifying treatment for Parkinson's disease.